 CAMBRIDGE, Mass., Oct. 12, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, today announced the presentation of new data at the 29th Annual Congress of the European Society of Gene Cell Therapy ESGCT meeting, taking place virtually from October 19-21, 2021. 